Table 1: Main characteristic of included studies.

First author Year No. of patients in the treatment group No. of patients in the control group Diagnostic criteria Intervention Control Duration of treatment (days) Duration of followup (months) CHD Group [21] 1981 138 138 Not reported Kangxingeng heji + BM BM N/A N/A Kou [22] 1983 133 135 WHO criteria Yiqihuoxue decoction and In + Xuejie powder + BM BM N/A N/A Chen [23] 1984 112 112 WHO criteria Yiqihuoxue decoction + Yiqihuoxue In + BM BM 35 N/A Liang [24] 1989 74 74 Author defined Tuoqingyanhu su + BM BM N/A N/A Xia [25] 1993 23 10 Not reported Dushen tang + thrombolysis Thrombolysis 3 N/A Li [26] 1994 60 64 WHO criteria Wenyanghuoxue decoction + BM BM 14 0.1 Li [27] 1994 18 15 WHO criteria Huangqi In + polarized solution BM + polarized solution 28 1 Yang [28] 1997 66 80 WHO criteria Shexiangbaoxin tablets + BM BM 360 12 Zhang [29] 1998 76 59 WHO criteria JianXin tablet + BM BM 30 1 Guo [30] 1999 243 259 WHO criteria Shenmai In + thrombolysis Thrombolysis 14 1.25 Li [31] 1999 51 50 WHO criteria Ligustrazine + compound danshen In + Chinese medicinal formulae + thrombolysis Thrombolysis 28 1 Zhang [32] 1999 52 47 WHO criteria Yiqihuoxuetongluo decoction + BM BM 28 1 Guo [33] 2000 143 159 WHO criteria Suxiao jiuxin pills + thrombolysis Thrombolysis 14 1.25 Han [34] 2000 38 44 WHO criteria Huangqi In + thrombolysis Thrombolysis 10 1 Li [35] 2000 28 19 WHO criteria Zhupi decoction + BM BM 7 0.25 Li QZ (a) [36]* 2000 66 80 WHO criteria Suxiao jiuxin pills + BM BM 360 12 Li QZ (b) [36]* 2000 66 72 WHO criteria Suxiao jiuxin pills + BM BM + Propranolol 360 12 Lu [37] 2000 21 21 WHO criteria Shuizhi In + BM BM 14 0.5 Yin [38] 2000 15 13 WHO criteria Shenmai In + Herba Erigerontis In + BM + thrombolysis BM + Thrombolysis 14 N/A Wu [39] 2001 54 49 WHO criteria Huangqi In + Dan-Shen In + BM BM 14 0.75 Bai [40] 2002 62 60 WHO criteria Shenmai In + BM BM 14 N/A Shi [41] 2002 58 56 Author defined Breviscapinun + BM + thrombolysis BM + Thrombolysis 20 0.67 Guan [42] 2003 30 30 WHO criteria Xingding In + BM BM 15 1 Zhang [43] 2003 45 45 Not reported Shenfu decoction+Xuefuzhupi decoction + BM BM 28 N/A Han [44] 2004 46 52 WHO criteria Shexiangbaoxin tablets + BM + thrombolysis BM + Thrombolysis 28 1 Li [45] 2004 32 18 WHO criteria Shexiangbaoxin tablets + BM + thrombolysis BM + Thrombolysis + placebo 90 3 Liu [46] 2004 41 96 WHO criteria Shenmai In + BM BM 15 N/A Yang [47] 2004 45 45 Not reported Huangqi In + thrombolysis Thrombolysis 7 6 Chen [48] 2005 35 34 Not reported Huangqi In + thrombolysis Thrombolysis 10 12 Deng [49] 2005 38 35 Not reported Xingnaojing In + BM BM 21 24 He [50] 2005 23 23 Author defined Kaixin capsule + BM + thrombolysis BM + thrombolysis 5 0.17 Li [51] 2005 83 83 Not reported Diaohuangqi In + BM BM 28 2 Liu [52]* 2005 30 22 WHO criteria Treatment based on TCM syndrome differentiation + thrombolysis Thrombolysis 28 1 Miao [53] 2005 64 62 WHO criteria Shengmai In + BM + thrombolysis BM + thrombolysis 15 2 Yang [54] 2005 45 45 Criteria from the Chinese Society of Cardiology Shexiangboxin tablets + BM BM N/A 3 Ding [55] 2006 15 15 WHO criteria Shengmai In + BM BM N/A N/A Du (a)[56]* 2006 1364 1371 Not reported Xuezhikang capsules + BM BM + placebo N/A 84 Du (b) [56]* 2006 1070 1065 Not reported Xuezhikang capsules + BM BM + placebo 1440 48 Li [57] 2006 31 32 Guideline from the European Society of Cardiology Shenfu In + BM BM 14 N/A Ma [58] 2006 25 25 Criteria from the Chinese Society of Cardiology Yuxingeng decoction + BM BM 28 1 Qi [59] 2006 48 46 WHO criteria Tanshinone II A sulfoacid In + BM + thrombolysis + PCI BM + thrombolysis + PCI 14 0.5 Shen [60] 2006 83 82 Author defined Shenfu In + BM BM N/A 0.25 Wang [61] 2006 228 162 WHO criteria Shenmai In + BM BM 14 1 Wei [62] 2006 31 37 WHO criteria Shenfu In + BM + thrombolysis BM + thrombolysis 7 0.25 Wu [63] 2006 19 21 WHO criteria Shenmai In + BM BM 20 1 Yang [64] 2006 48 49 Not reported Xuezhikang capsules + BM BM + placebo N/A 72 Chen [65] 2007 30 30 WHO criteria Tongxinluo capsule + BM BM 56 2 Li [66] 2007 45 45 Author defined Guanxinning In + BM BM 15 6 Liang [67] 2007 90 68 WHO criteria Shengmai In or Shenmai In + treatment based on TCM syndrome Differentiation + BM + thrombolysis BM N/A N/A Pan [68] 2007 20 20 WHO criteria Tongxinluo capsule + BM BM N/A 1 Zhai [69] 2007 38 30 Criteria from Chinese Society of Cardiology Shenmai In + BM BM 10 N/A Ding [70] 2008 23 23 Author defined Shengmai In + BM BM N/A N/A Lan [71] 2008 130 128 WHO criteria Xinmaitong capsules + BM BM 30 1 Yu [72] 2008 100 96 Author defined Shexiang Baoxin tablets + BM BM 10 1 Yu [73] 2008 32 32 Author defined Yinxingdamo In + BM + thrombolysis BM + thrombolysis 14 0.5 Zhang [74] 2008 27 27 WHO criteria Shenmai In + Shuxuening In + BM BM 28 N/A Gao [75] 2009 60 60 WHO criteria Danhong In + BM BM N/A 0.5 Lin [76] 2009 25 25 Author defined Compound danshen dripping pills + BM BM N/A 1 Liu [77] 2009 16 16 Author defined Tanshinone II A sulfoacid In + BM BM 7 3 Song [78] 2009 36 34 Author defined Tongxinluo capsule + Shenmai In + Gegensu In + BM BM 28 N/A Yuan [79] 2009 38 38 WHO criteria Shenmai In + thrombolysis Thrombolysis 10 1 Zhao [80] 2009 50 48 Not reported Tongxinluo capsule + BM + thrombolysis BM + thrombolysis N/A 12 Zuo [81] 2009 80 80 Criteria from Chinese Society of Cardiology Breviscapinun + BM BM 14 1 Guo [82] 2010 48 45 Not reported Compound Danshen tablet + BM BM N/A 12 Xu [83] 2010 32 30 Author defined Treatment based on TCM syndrome differentiation + BM BM 28 1

BM: routine biomedical treatment as defined by the investigators; In: injection; N/A: not reported. *Two RCTs reported in one publication.